Clinical trial
A Randomized Study Evaluating the Feasibility and Activity of Three Different…
NCT00191490 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191490 |
|---|---|
| Title | A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer |
| Official title | A Multicenter Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel (RP56976, TAXOTERE *) and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non Small Cell… |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Gemcitabine, docetaxel, cisplatin |
| Enrollment | 162 |
| Start date | Jul 1, 2002 |
| Completion | May 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: